You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
SBC: NEWVENTUREIQ LLC Topic: 102Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing brain penetrance of caspase-6 inhibitors to treat neurodegenerative diseases
SBC: ELGIA THERAPEUTICS, INC. Topic: RPROJECT SUMMARY/ABSTRACT The cysteine protease caspase-6 (Casp6) has been associated with neurodegenerative diseases for over fifteen years. In Alzheimer’s disease (AD), Casp6 is colocalized with amyloid plaques and tau tangles in human brain, and both human and animal model data indicate that activated Casp6 contributes to neuronal inflammation, neurodegeneration, and cleavage of proteins to to ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Solving Sepsis: Early Identification and Prompt Management Using Machine Learning
SBC: Cohere-Med, Inc. Topic: 300Abstract This fast-track STTR application proposes to enhance, validate, and scale Sepsis Watch, a deep learning sepsis detection and management system built using data from the Emergency Department (ED) Duke University Hospital (DUH). The proposal will extend and enhance Sepsis Watch to EDs, general inpatient wards, and intensive care unit (ICU) settings across multiple health systems in the Unit ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeted ColQ gene therapy for Congenital Myasthenic Syndromes
SBC: Amplo Biotechnology, Inc. Topic: 106PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Inducible HMGB1 antagonist for viral-induced acute lung injury.
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NHLBIFor more than a decade, our work has focused on development of therapeutic interventions for viral- and bacterial-induced acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS). Significantly, we identified the Toll-like receptor 4 (TLR4) signaling pathway as key to the host response to influenza and secondary bacterial infection following influenza. We also identif ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes
SBC: VALA SCIENCES, INC. Topic: NHLBICardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a portable beat-to-beat fetal ECG system
SBC: AUSCULTECH DX LLC Topic: NICHDProject Summary There are 24,000 stillbirths per year in the United States, and 2.6 million stillbirths per year worldwide, with no significant decrease in the last decade. Abnormal fetal heart rhythms, such as long QT syndrome, are thought to play an important role in these deaths, and may cause 3- 10% of unexplained stillbirths. This is in addition to known fetal arrhythmias, which affect 1-3% o ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Glove-based Tactile Streaming of Braille Characters and Digital Images for the Visually Impaired
SBC: HAPTX INC Topic: NEIThis project will achieve a computerized system that supplies digital content, both lexical and graphical, suitable for children, students and working adults of the Visually Impaired (VId) community, to increase their autonomy and potentiate their Quality of Life and societal contribution. While there is notable academic research, such as a high-density pin display tablet, there is no commercial, ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A decellularized porcine placenta matrix hydrogel for management of radiation-induced proctitis
SBC: Briopryme Biologics, Inc. Topic: 102PROJECT SUMMARY Radiation therapy is a widely used treatment modality for pelvic malignancies such as prostate and cervical cancer; however, the high doses needed to confer therapeutic benefit often inflict significant damage on the normal issue in and surrounding the radiation field. The most frequent complication of pelvic radiation is proctitis, which nearly all patients experience acutely and ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy
SBC: NEURAEGIS INC Topic: 103AbstractEpilepsy is the most prevalent neurological diseases after migraines. Current antiepileptic drug treatments mainly attempt to reduce excitation or enhance inhibition in order to control seizures. Unfortunately, such therapeutics result in a number of undesirable side-effects, and demonstrate limited efficacy against drug- resistant cases of epilepsy. So far, no treatment has been developed ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health